LEGN (Legend Biotech) Interest Expense: $-22 Mil (TTM As of Mar. 2026)


LEGN Legend Biotech Corp LEGN
71 GF Score
Price $29.93
GF Value $99.04
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech Interest Expense?

Legend Biotech LEGN -0.03% 71 Interest Expense is $-22 Mil as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 71/100 and a GF Value™ of $99.04 (Possible Value Trap). The stock has 3 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Legend Biotech's interest expense for the three months ended in Mar. 2026 was $ -6 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-22 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Legend Biotech's Operating Income for the three months ended in Mar. 2026 was $ -50 Mil. Legend Biotech's Interest Expense for the three months ended in Mar. 2026 was $ -6 Mil. Legend Biotech did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Legend Biotech  (NAS:LEGN) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Legend Biotech's Interest Expense for the three months ended in Mar. 2026 was $-6 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-50 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $112 Mil.

Legend Biotech's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Legend Biotech did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Legend Biotech Interest Expense Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Interest Expense Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial -0.90 -10.80 -21.80 -21.60 -21.40

Legend Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.10 -5.22 -5.64 -5.48 -5.50
LEGN
71GF Score
Legend Biotech Corp LEGN
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-22 Mil mean?
Legend Biotech (LEGN) has a Interest Expense of $-22 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Interest Expense too high?
Legend Biotech's current Interest Expense is $-22 Mil. Overall, Legend Biotech has a GF Score™ of 71/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Interest Expense compare to TVTX and ORKA?
Legend Biotech's Interest Expense of $-22 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Legend Biotech and its competitors. Legend Biotech's current Interest Expense is $-22 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $99.04, compared to a current price of $29.93 — trading 69.8% below its estimated fair value. The current Interest Expense is $-22 Mil. Legend Biotech's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Legend Biotech (LEGN), the current Interest Expense is $-22 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (LEGN) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of $29.93 is trading 69.8% below its estimated GF Value™ of $99.04. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for LEGN:

  • Interest Expense: $-22 Mil
  • GF Value™: $99.04 vs. price of $29.93 (69.8% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges 9LB:Germany
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
71GF Score

Get the complete analysis for LEGN

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.93
Price
$99.04
GF Value